Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Reports by T. Town and co-researchers describe recent advances in immunization
June 3rd, 2009
According to a study from the United States, "In a seminal report in 1999, Schenk and colleagues demonstrated that vaccination of a mouse model of Alzheimer's disease (AD) with amyloid-beta(1-42) peptide (A beta(1-42)) and adjuvant resulted in striking mitigation of AD-like pathology - giving rise to the field of AD immunotherapy. Later studies confirmed this result in other mouse models of AD and additionally showed cognitive improvement after A beta vaccination." "Based on these results, early developmental clinical trials ensued to immunize AD patients with A beta(1-42) plus adjuvant (so-called ''active'' A beta immunotherapy; trade name AN-1792; Elan...
Source: Vaccine Weekly (2009-06-03)
|
